We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Sandoz Sued Over Schizophrenia Drug Patent

Law360 (March 5, 2007, 12:00 AM EST) -- A Japanese pharmaceutical company has filed a patent infringement suit against the generics arm of Novartis AG in response to the subsidiary’s bid to obtain U.S. regulatory approval for a generic version of schizophrenia and bipolar disorder treatment Abilify.

Tokyo-based Otsuka Pharmaceutical Co. Ltd. filed the lawsuit Friday in New Jersey against Sandoz Inc., seeking to bar Sandoz’ proposed generics from entering the U.S. market until the expiration of an Otsuka patent.

At issue is U.S. Patent Number 5,006,528, entitled “carbostyril derivatives,” which was issued and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.